10074 related articles for article (PubMed ID: 14682375)
1. Cytokine immuno-gene therapy for treatment of brain tumors.
Lichtor T; Glick RP
J Neurooncol; 2003 Dec; 65(3):247-59. PubMed ID: 14682375
[TBL] [Abstract][Full Text] [Related]
2. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.
Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP
Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052
[TBL] [Abstract][Full Text] [Related]
3. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
Glick RP; Lichtor T; de Zoeten E; Deshmukh P; Cohen EP
Neurosurgery; 1999 Oct; 45(4):867-74. PubMed ID: 10515482
[TBL] [Abstract][Full Text] [Related]
4. Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors.
Glick RP; Lichtor T; Panchal R; Mahendra A; Cohen EP
J Neurooncol; 2003; 64(1-2):139-46. PubMed ID: 12952294
[TBL] [Abstract][Full Text] [Related]
5. Immunogene therapy as a treatment for malignant brain tumors in young mice.
Glick RP; Lichtor T; Lin H; Tarlock K; Cohen EP
J Neurosurg; 2006 Jul; 105(1 Suppl):65-70. PubMed ID: 16871873
[TBL] [Abstract][Full Text] [Related]
6. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.
Lichtor T; Glick RP; Tarlock K; Moffett S; Mouw E; Cohen EP
Cancer Gene Ther; 2002 May; 9(5):464-9. PubMed ID: 11961669
[TBL] [Abstract][Full Text] [Related]
7. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
8. Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice.
Deshmukh P; Glick RP; Lichtor T; Moser R; Cohen EP
J Neurosurg; 2001 Feb; 94(2):287-92. PubMed ID: 11213967
[TBL] [Abstract][Full Text] [Related]
9. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells.
Kim TS; Cohen EP
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):24-35. PubMed ID: 8081557
[TBL] [Abstract][Full Text] [Related]
10. Survival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system.
Griffitt W; Glick RP; Lichtor T; Cohen EP
Neurosurgery; 1998 Feb; 42(2):335-40. PubMed ID: 9482184
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer.
Lichtor T; Glick RP; Lin H; O-Sullivan I; Cohen EP
Cancer Gene Ther; 2005 Aug; 12(8):708-14. PubMed ID: 15803143
[TBL] [Abstract][Full Text] [Related]
12. Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo.
Glick RP; Lichtor T; Kim TS; Ilangovan S; Cohen EP
Neurosurgery; 1995 Mar; 36(3):548-55. PubMed ID: 7753355
[TBL] [Abstract][Full Text] [Related]
13. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system.
Ewend MG; Thompson RC; Anderson R; Sills AK; Staveley-O'Carroll K; Tyler BM; Hanes J; Brat D; Thomas M; Jaffee EM; Pardoll DM; Brem H
J Immunother; 2000; 23(4):438-48. PubMed ID: 10916753
[TBL] [Abstract][Full Text] [Related]
14. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
Aruga A; Aruga E; Chang AE
Cancer Res; 1997 Aug; 57(15):3230-7. PubMed ID: 9242454
[TBL] [Abstract][Full Text] [Related]
15. Enhanced immunity to intracerebral breast cancer in mice immunized with a cDNA-based vaccine enriched for immunotherapeutic cells.
Lichtor T; Glick RP; Feldman LA; Osawa G; Hardman J; O- Sullivan I; Cohen EP
J Immunother; 2008 Jan; 31(1):18-27. PubMed ID: 18157008
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts.
Spagnolo A; Glick RP; Lin H; Cohen EP; Feinstein DL; Lichtor T
J Neurosurg; 2007 Feb; 106(2):299-305. PubMed ID: 17410715
[TBL] [Abstract][Full Text] [Related]
17. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors.
Thompson RC; Pardoll DM; Jaffee EM; Ewend MG; Thomas MC; Tyler BM; Brem H
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):405-13. PubMed ID: 9041459
[TBL] [Abstract][Full Text] [Related]
18. Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines.
Tseng SH; Hwang LH; Lin SM
J Immunother; 1997 Sep; 20(5):334-42. PubMed ID: 9336740
[TBL] [Abstract][Full Text] [Related]
19. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma.
Kim TS; Russell SJ; Collins MK; Cohen EP
Int J Cancer; 1993 Nov; 55(5):865-72. PubMed ID: 8244584
[TBL] [Abstract][Full Text] [Related]
20. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells.
Lichtor T; Glick RP; Kim TS; Hand R; Cohen EP
J Neurosurg; 1995 Dec; 83(6):1038-44. PubMed ID: 7490618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
